Moderna Stock Surges 177% on Melanoma Vaccine Trial Results

Moderna Stock Soars 131% After Cancer Trial Success, Short Sellers Lose $4.8B

MRNA

Crypto markets are currently driven by macro liquidity, regulatory clarity, and BTC dominance, not biotech headlines. While a positive biotech story could theoretically lift risk appetite, the correlation is weak and often lagged. The approval does not alter the fundamental drivers of digital assets.

Moderna

Moderna's mRNA flu vaccine has been approved.